吴剑波

职称：教授

学院/部门： 四川省高等学校天然药物活性物质与分子药理重点实验室

药物与功能性食品研究中心

泸州医学院

电邮地址：jbwucn@163.com

电话：(0830) 3161702

传真：(0830) 3161702

办公室：含光楼 817

邮寄地址：四川省泸州市江阳区忠山路 3 段 319 号

教研领域

教学科目：血管生物学

研究方向：心血管药理、血管形成机制及干预、血栓形成机制及干预

学历

2001-2003 University of Ulm 医学博士

1997-1999 广东医学院病理生理学/硕士

1985-1990 泸州医学院医学系/临床医学

教学经验

2010. 9-现在 泸州医学院

1994.6-1999.10 广东医学院

1990.9-1999.9 泸州医学院

学术成果

期刊文章: (*, corresponding author)

1. Ren M, Li R, Luo M, Chen N, Deng X, Yan K, Zeng M, **Wu J***. Endothelial cells butnot platelets are the major source of Toll-like receptor 4 in the arterialthrombosis and tissue factor expression in mice. Am J Physiol Regul Integr Comp Physiol. 2014;307(7):R901-907.

2. Ji Y, Fish PM, Strawn TL, Lohman AW, **Wu J**, Szalai AJ, Fay WP. C-Reactive Protein Induces Expression of Tissue Factor and Plasminogen Activator Inhibitor-1 and Promotes Fibrin Accumulation in Vein Grafts. J Thromb Haemost. 2014;12(10):1667-1677.

3. Li R, Luo M, Ren M, Chen N, Xia J, Deng X, Zeng M, Yan K, Luo T, **Wu J***. Vitronectin regulation of vascular endothelial growth factor-mediated angiogenesis. J Vasc Res. 2014; 51:110-117.

4. Li R, Ren M, Chen N , Luo M, Deng X, Xia J, Yu G, Liu J, He B, Zhang X, Zhang Z, Zhang X, Ran B and **Wu J***. Presence of intratumoral platelets is associated with tumor vessel structure and metastasis. BMC Cancer 2014; 14:167.

5.Zhang Z, Chen N, Liu JB, **Wu JB**, Zhang J, Zhang Y, Jiang X. Protective effect of resveratrol against acute lung injury induced by lipopolysaccharide via inhibiting the myd88-dependent Toll-like receptor 4 signaling pathway. Mol Med Rep. 2014;10(1): 101-106.

6. 曾敏，罗茂，李蓉，邓鑫，**吴剑波***. 微小 RNA 调控血管平滑肌表型转化的研究进展.中华心血管杂志，2014,42(9): 1-4.

7. 邓鑫,罗茂,李蓉,**吴剑波***.血管周细胞在肿瘤血管生成和转移过程中的作用研究进展[J].中国肿瘤临床,2013,(8):483-485.

8. Li R, Ren M, Chen N, Luo M, Zhang Z, **Wu J***. Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions. PLoS One. 2012;7(5):e37195.

9. Li R, Ren M, Luo M, Chen N, Zhang Z, Luo B, **Wu J***. Monomeric C-reactive protein alters fibrin clot properties on endothelial cells. Thromb Res. 2012;129(5):e251-6.

10. Zhang Z, Yang Y, Hill MA, **Wu J***. Does C-reactive protein contribute to atherothrombosis via oxidant-mediated release of pro-thrombotic factors and activation of platelets? Front Physiol. 2012;3:433.

11. 罗茂,任美萍,**吴剑波***. 血小板微小 RNA 研究进展[J].中华心血管病志 2012,40(8):714-717.

12. Garg N, Goyal N, Strawn TL, **Wu J**, Mann KM, Lawrence DA, Fay WP. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost. 2010; 8: 1847-1854.

13. Yang Y, Wu X, Gui P, **Wu J**, Sheng JZ, Ling S, Braun P, Davis GE, Davis MJ. Avβ3 integrin engagement increases BK channel current and Ca^{2+} sensitivity through c-Src mediated channel phosphorylation. J Biol Chem. 2010； 285(1):131-141.

14. **Wu J***. Peng L, McMahonGA, RabbaniAB, Lawrence DA, Fay WP. Recombinant plasminogen activator Inhibitor-1 inhibits intimal hyperplasia. *Arterioscler Thromb Vasc Biol*. 2009; 29(10):1565-1570.

15.Hyder SM, Liang Y, **Wu J**. Estrogen regulation of thrombospondin-1 in human breast cancer cells. Int. J. Cancer 2009; 125(5):1045-1053.

16. Hyder SM, Liang Y, **Wu J**, and Welbern V. Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells. Endocr Relat Cancer. 2009;16(3):809-817.

17. **Wu J***. Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. *Arterioscler Thromb Vasc Biol.* 2008; 28(4):698-704. Editorial comment.

18. Zhou W, Liu Z, **Wu J**, Liu J, Hyder SM, Antoniou E, Lubahn DB. Identification and transcriptional activity characterization of two novel splicing isoforms of human ERR â Journal of Clinical Endocrinology & Metabolism 2006; 91(2):569-579.

19. **Wu J**, Liang Y, Nawaz Z, and Hyder SM. Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: Implications for treatment resistance. International Journal of Oncology 2005; 27(6): 1647-1659.

20. **Wu J**, Brandt S, Hyder SM. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells. Molecular Endocrinology 2005; 19(2):312-326.

21. Liang Y, **Wu J**, Hyder SM. p53-dependent inhibition of progestin-induced VEGF expressionin human breast cancer cells. J Steroid Biochem Mol Biol. 2005; 93(2-5):173-182.

22. **Wu J**, Richer J, Horwitz KB and Hyder SM. Progestin-dependent induction of VEGF in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Research 2004; 64(6): 2238-2244.

23. Babiak A, Schumm AM, Wangler, C, Loukas M, **Wu J**, Dombrowski S, Matuschek C, Kotzerke J, Dehio C, Waltenberger J.Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion. Cardiovascular Research 2004; 61(4):789-795.